Thalidomide and derivatives: Immunological investigations of tumour necrosis factor-alpha (TNF-α) inhibition suggest drugs capable of selective gene regulation

Clinical and Experimental Immunology

Volumn 110, Issue 2, 1997, Pages 151-154

  McHugh, S M ^a,b   Rowland, T L ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b HUNTINGDON LIFE SCIENCES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CELL SPECIFICITY; DRUG EFFICACY; DRUG INHIBITION; ERYTHEMA NODOSUM LEPROSUM; GENETIC REGULATION; IMMUNOMODULATION; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0030730162     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1997.tb08310.x     Document Type: Review

References (50)

1. Hennies H-H, Günzler WA, Flohé L. Influence of supidimide on brain neurotransmitter systems of rats and mice. Arzneimittelforschugh 1984; 34:1471-80.
2. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6:303.
3. Sampaio EP, Kaplan G, Miranda A et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168:408-14.
4. Gardner-Medwin J, Smith N, Powell R. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53:828-32.
5. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81:219-23.
6. Powell R. New roles for thalidomide [editorial]. BMJ 1996; 313:377-8.
7. Larsson H. Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). J Intern Med 1990; 228:405-7.
8. Postema PT, den-Haan P, van-Hagen PM, van-Blankenstein M. Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996; 8:929-31.
9. Makonkawketoon S, Limson-Pobre RNR, Moreiera AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90:5794-978.
10. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes OJ. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989; 16:158-63.
11. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32:866-9.
12. Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Eng J Med 1992; 326:1055-8.
13. Vogelsang GB, Hess AD, Gordon G, Brundrette R. Thalidomide induction of bone marrow transplantation tolerance. Transplantation Proc 1987; 19:2658.
14. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73:333-46.
15. Beauparlant P, Hiscott J. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev 1996; 7:175-90.
16. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; ii: 1958-60.
17. Lenz W. Thalidomide and congenital abnormalities. Lancet 1962; i:45-48.
18. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
19. Rowland TL, McHugh SM, Deighton J, Dearman RL, Ewan PW, Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Clin Exp Immunol 1997, in press.
20. Fernandez LP, Schlegel PG, Baker J, Chen Y, Chao NJ. Does thalidomide affect IL-2 response and production? Exp Hematol 1995; 23:978-85.
21. Neubert R, Nogueira AC, Neubert D. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993; 67:1-17.
22. Shannon EJ, Howe RC, McLean K, Hastings RC. Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential. Immunopharmacol Immunotoxicol 1994; 16:717-29.
23. McHugh SM, Rifkin IR, Deighton J et al. The immunosuppressive drug thalidomide induces T-helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99:160-7.
24. Hauschild A, Kroeger H, Mitchison NA, Ugrinovic S, Zwingenberger K. Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift. Clin Exp Immunol 1997; 108:428-31.
25. Azuma A, Miyachi H, Shibata Y, Hashimoto Y, Iwasaki S. Augmentation by phthalimides of phorbol ester-induced expression of tumor necrosis factor alpha message. Biol Pharm Bull 1996; 19:1001-3.
26. Miyachi H, Azuma A, Hioki E, Iwasaki S, Kobayashi Y, Hashimoto Y. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem Biophys Res Commun 1996; 224:426-30.
27. Miyachi H, Azuma A, Hioki E, Iwasaki S, Kobayashi Y, Hashimoto Y. Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence. Biochem Biophys Res Commun 1996; 226:439-44.
28. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A. Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31:109-16.
29. Shannon EJ, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol 1996; 18:59-72.
30. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 77:1675-80.
31. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 1996; 93:7552-6.
32. Kopp EB, Ghosh S. NF-κB and Rel proteins in innate immunity. Adv Immunol 1995; 58:1-27.
33. Rao A. NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today 1994; 15:274-81.
34. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996; 16:459-67.
35. Lawrence HJ, Largman C. Homeobox genes in normal hematopoiesis and leukemia. Blood 1992; 80:2445-53.
36. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Brit J Pharmacol 1965; 25:324-37.
37. Becker R, Frankus E, Graudums I, Günzler WA, Helm F-C, Flohé L. The metabolic fate of supidimide in the rat. Arzneimittelforschugh 1982; 31:1101-11.
38. Wnendt S, Finkam M, Winter W, Ossig J, Raube G, Zwingenberger K. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues. Chirality 1996; 8:390-6.
39. Nishimura K, Hashimoto Y, Iwasaki S. (S)-form of alpha-methyl-N (alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem Pharm Bull Tokyo 1994; 42:1157-9.
40. Nachbaur D, Herold M, Gächter A, Niederwieser D. Immune response modulation in vitro by thalidomide and its derivatives EM-12 micro. Supidimide (EM-87) and MA-3. Potent inhibition of immune cell activation by the derivative MA-3, but not by thalidomide. EM-12 or EM-87. Clin Exp Immunol 1997; in press.
41. Muller GW, Corral LG, Shire MG et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996; 39:3238-40.
42. Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2:506-15.
43. Kaplan G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 1994; 191:564-8.
44. Aarestrup FM, Goncalves-da-Costa SC, Sarno EN. The effect of thalidomide on BCG-induced granulomas in mice. Braz J Med Biol Res 1995; 28:1069-76.
45. Netea MG, Blok WL, Kullberg BJ et al. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995; 171:393-9.
46. Niwayama S, Turk BE, Liu JO. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem 1996; 39:3044-5.
47. Sasaki K, Shibata Y, Hashimoto Y, Iwasaki S. Benzylphthalimides and phenethylphthalimides with thalidomide-like activity on the production of tumor necrosis factor alpha. Biol Pharm Bull 1995; 18:1228-33.
48. Watkins LR, Goehler LE, Relton J, Brewer MT, Maier SF. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res 1995; 692:244-50.
49. Takahashi S, Kapas L, Krueger JM. A tumor necrosis factor (TNF) receptor fragment attenuates TNF-alpha- and muramyl dipeptide-induced sleep and fever in rabbits. J Sleep Res 1996; 5:106-14.
50. Peterson PK, Hu S, Sheng WS et al. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995; 172:1137-40.